106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2021 All rights reserved
ASCOCOL11213
Disclaimer
is pocket card is derived om recommendations in the American Society of Clinical Oncology
Guideline. is resource is a practice tool based on ASCO
®
practice guidelines and is not intended
to substitute for the independent professional judgment of the treating physician. Practice guidelines
do not account for individual variation among patients. is pocket card does not purport to suggest
any particular course of medical treatment. Use of the practice guidelines and this resource are
voluntary. e practice guidelines and additional information are available at www.asco.org/
gastrointestinal-cancer-guidelines. Copyright © 2021 by American Society of Clinical Oncology.
All rights reserved.
Abbreviations
ACT, Adjuvant chemotherapy; CAPOX, capecitabine and oxaliplatin; CI, confidence
interval; ctDNA, circulating tumor DNA; DFS, disease free survival; dMMR, deficient
mismatch repair; FOLFOX, fluorouracil, leucovorin and oxaliplatin; FU, fluorouracil; HR,
hazard ratio; IDEA, International Duration Evaluation of Adjuvant Chemotherapy; MSI,
microsatellite instability; MSS, microsatellite stable; pMMr, proficient mismatch repair
Source
Baxter NN, et al. Adjuvant erapy for Stage II Colon Cancer: ASCO Guideline Update.
J Clin Oncol. 2021 Dec 22. doi: 10.1200/JCO.21.02538
ASCO believes that cancer clinical trials are vital to inform medical decisions and
improve cancer care and that all patients should have the opportunity to participate.
Additional information, which may include data supplements, slide sets, and other clinical
tools and resources, is available at www.asco.org/gastrointestinal-cancer-guidelines.